Nezam H. Afdhal Net Worth

The estimated Net Worth of Nezam H. Afdhal is at least $48.6 Thousand dollars as of 9 September 2016. Nezam Afdhal owns over 2,400 units of Spring Bank Pharmaceuticals stock worth over $48,582 and over the last 8 years Nezam sold SBPH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Nezam Afdhal SBPH stock SEC Form 4 insiders trading

Nezam has made over 4 trades of the Spring Bank Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Nezam bought 2,400 units of SBPH stock worth $30,000 on 9 September 2016.

The largest trade Nezam's ever made was buying 2,600 units of Spring Bank Pharmaceuticals stock on 12 August 2016 worth over $29,458. On average, Nezam trades about 989 units every 3 days since 2016. As of 9 September 2016 Nezam still owns at least 40,150 units of Spring Bank Pharmaceuticals stock.

You can see the complete history of Nezam Afdhal stock trades at the bottom of the page.

What's Nezam Afdhal's mailing address?

Nezam's mailing address filed with the SEC is 86 South St, Hopkinton, MA 01748, USA.

Insiders trading at Spring Bank Pharmaceuticals

Over the last 9 years, insiders at Spring Bank Pharmaceuticals have traded over $50,400 worth of Spring Bank Pharmaceuticals stock and bought 237,689 units worth $2,510,768 . The most active insiders traders include Todd C Brady, Scott Andrew Smith, and Kurt M Eichler. On average, Spring Bank Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $8,517. The most recent stock trade was executed by Garrett Winslow on 19 November 2020, trading 6,250 units of SBPH stock currently worth $7,563.

What does Spring Bank Pharmaceuticals do?

Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.

Complete history of Nezam Afdhal stock trades at Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals executives and stock owners

Spring Bank Pharmaceuticals executives and other stock owners filed with the SEC include:

• Kurt M Eichler,
  Director
• Martin J Driscoll,
  President and CEO
• David Arkowitz,
  Director
• Christiana Bardon,
  Director
• Timothy P Clackson,
  Director
• Nezam H. Afdhal,
  Chief Medical Officer
• Todd C Brady,
  Director
• Jonathan Bates,
  Director
• Scott Andrew Smith,
  Director
• Jonathan Freve,
  CFO & Treasurer
• Radhakrishnan P. Iyer,
  Chief Scientific Officer
• Garrett Winslow,
  General Counsel and Secretary
• Pamela M. Klein,
  Director
• Lori Firmani,
  VP of Finance and Treasurer